Long‐term efficacy of rituximab versus intravenous cyclophosphamide for severe ANCA‐associated vasculitis in multicenter REVEAL cohort study
Journal of Internal Medicine · 2025-11 · 298 (5) · 504-515
DOI: 10.1111/joim.70024 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Internal Medicine, online erschienen am 22.09.2025. Verfasst von Shogo Matsuda und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine IV, Division of Rheumatology, Osaka Medical and Pharmaceutical University, Osaka, Japan. Hauptthemen laut MEDLINE: Rituximab, Cyclophosphamide, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Immunosuppressive Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The optimal remission induction therapy for severe antineutrophil cytoplasmic antibody‐associated vasculitis (AAV) remains unclear. This study evaluated the effectiveness of rituximab (RTX) as a remission induction therapy for severe AAV compared with intravenous cyclophosphamide (IVCY).
Methods
Patients with microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA) treated with systemic glucocorticoids (GCs) and IVCY or RTX as initial remission induction therapy in multicenter REVEAL study between 1991 and 2024 were enrolled. We compared efficacy and safety outcomes between the two groups. Effectiveness was evaluated using all‐cause mortality, GC‐remission rate, relapse rate, and end‐stage renal disease (ESRD) progression rate. Safety was evaluated based on complications from severe infections. Inverse probability of treatment weighting (IPTW) was applied for selection bias.
Results
Of 555 patients with AAV, 178 with severe MPA or GPA were identified (IVCY group: N = 133, RTX group: N = 45). After adjustment by IPTW, no significant differences in baseline clinical characteristics were observed between them. The 10‐year survival rate and GC‐remission rate at 6 months were significantly higher in the RTX group ( p = 0.04, p = 0.017, respectively). ESRD progression and relapse rates were comparable between two groups. Regarding safety, 15.2% of patients in the IVCY group died due to severe infections, whereas none did in the RTX group ( p = 0.007).
Conclusions
RTX demonstrated superior efficacy in improving survival and achieving GC remission, with fewer infection‐related deaths compared to IVCY in patients with severe AAV. These findings reveal the efficacy and safety of RTX as a remission induction therapy in real‐world Japanese clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine IV, Division of Rheumatology, Osaka Medical and Pharmaceutical University, Osaka, Japan.
- Department of Medical Statistics, Research & Development Center, Osaka Medical and Pharmaceutical University, Osaka, Japan.
- Department of Internal Medicine IV, Division of Neurology, Osaka Medical and Pharmaceutical University, Osaka, Japan.
- Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
- Department of Clinical Immunology, Osaka Metropolitan University, Osaka, Japan.
- Division of Clinical Immunology and Rheumatology, Yodogawa Christian Hospital, Osaka, Japan.
ORCID-Profile: Ryosuke Hiwa
Zitieren
APA
Matsuda, S., Kotani, T., Nishioka, D., Okazaki, A., Masuda, Y., Taniguchi, T., Shoji, M., Yoshida, T., Hiwa, R., Shiomi, M., Watanabe, R., Hatta, M., Ito, N., Fujiki, Y., Miyake, H., Yamamoto, W., Hashimoto, M., & Takeuchi, T. (2025). Long‐term efficacy of rituximab versus intravenous cyclophosphamide for severe ANCA‐associated vasculitis in multicenter REVEAL cohort study. Journal of Internal Medicine, 298(5), 504-515. https://doi.org/10.1111/joim.70024
Vancouver
Matsuda S, Kotani T, Nishioka D, Okazaki A, Masuda Y, Taniguchi T, et al. Long‐term efficacy of rituximab versus intravenous cyclophosphamide for severe ANCA‐associated vasculitis in multicenter REVEAL cohort study. Journal of Internal Medicine. 2025;298(5):504-515. doi:10.1111/joim.70024
BibTeX
@article{Matsuda2025,
author = {Matsuda, Shogo and Kotani, Takuya and Nishioka, Daisuke and Okazaki, Ayana and Masuda, Yuichi and Taniguchi, Tomoki and Shoji, Mikihito and Yoshida, Tsuneyasu and Hiwa, Ryosuke and Shiomi, Mayu and Watanabe, Ryu and Hatta, Muneyuki and Ito, Naoko and Fujiki, Yohei and Miyake, Hirofumi and Yamamoto, Wataru and Hashimoto, Motomu and Takeuchi, Tohru},
title = {Long‐term efficacy of rituximab versus intravenous cyclophosphamide for severe ANCA‐associated vasculitis in multicenter REVEAL cohort study},
journal = {Journal of Internal Medicine},
year = {2025},
volume = {298},
number = {5},
pages = {504--515},
doi = {10.1111/joim.70024}
}
EUVIMED